GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Additional Paid-In Capital

Genexine (XKRX:095700) Additional Paid-In Capital : ₩354,085 Mil(As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Genexine Additional Paid-In Capital?


Genexine's quarterly additional paid-in capital declined from Sep. 2023 (₩652,890 Mil) to Dec. 2023 (₩645,956 Mil) but then stayed the same from Dec. 2023 (₩645,956 Mil) to Mar. 2024 (₩354,085 Mil).

Genexine's annual additional paid-in capital declined from Dec. 2021 (₩562,715 Mil) to Dec. 2022 (₩561,656 Mil) but then increased from Dec. 2022 (₩561,656 Mil) to Dec. 2023 (₩645,956 Mil).

Genexine Additional Paid-In Capital Historical Data

The historical data trend for Genexine's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Additional Paid-In Capital Chart

Genexine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 457,525.46 551,128.05 562,715.48 561,656.07 645,956.41

Genexine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 643,162.86 652,889.67 652,889.67 645,956.41 354,085.49

Genexine Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Genexine Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genexine's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Additional Paid-In Capital
Comparable Companies
XKRX:228760 XKRX:216080 XKRX:323990 XKRX:334970 XKRX:005690 XKRX:358570 XKRX:199800 XKRX:115450 XKRX:060590 XKRX:011000 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488
Website
http://www.genexine.com
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines